Introduction
Multiple sclerosis (MS) is a chronic disabling neurological disease which has a prevalence in the United Kingdom of approximately 100 per 100 000 and is estimated to account for 92000 bed days in the National Health Service in England and Wales every year. It is one of the major causes of disability and, since it has a peak onset between the ages of 25 and 35 years, it causes considerable social problems to the families of sufferers.'It is a disease which varies considerably in its effect upon the patient; at one end of the spectrum, it may present few clinical signs and may not even be diagnosed in life -the so called benign MS; at the other extreme, it can lead to significant problems with vision, co-ordination, movement, sensation, intellect and sphincter control and result in considerable disability -the fulminant form of the disease.
It is recognized to arise from an immunological attack on the myelin or insulation of the nervous system resulting in demyelination and ultimately gliosis or scarring of the brain and spinal cord. The cause of the disease remains unknown, but studies of the epidemiology, clinical features and immune status of patients, have led to the hypothesis that a chronic virus infection in susceptible individuals results in the autoimmune destruction of myelin and the consequent development of the disease.
Diet and MS
In a disease such as MS, when the cause is unknown and there is no recognized curative or preventative therapy, it is Abbreviations used: MS, multiple sclerosis; PUFA, polyunsaturated fatty acid inevitable that patients and their relatives will turn to 'alternative medicine' for some form of relief. One such therapy is dietary manipulation and, in MS, most of the studies of dietary manipulation have been related to polyunsaturated fatty acids (PUFA). The rational for such therapy has been based, not upon the role of PUFA in cell membranes and therefore in the myelin which is the target of the disease, but upon epidemiological evidence and biochemical studies which have identified a relationship between PUFA and MS.
Epidemiology. One of the most consistent epidemiological findings in MS has been the higher prevalence of the disease in populations who consume diets rich in animal fats containing saturated fatty acids (Alter et al., 1974) . The initial observation was made by Swank (1950) that the incidence of MS in Norway fell during the German Occupation and increased after the end of the war. He suggested that this finding might relate to a reduction in dietary fat during the hostilities. In 1952, Swank and others extended these observations and demonstrated that the incidence of MS was higher in the inland dairy eating areas of Norway than in the coastal fisheating population. He suggested that animal fats were harmful and could result in platelet aggregation with subsequent small vessel occlusion which might cause perivascular plaques. Matthews ( 1985) has reviewed the other suggestions which have been made to explain the apparent relationship between the saturated fatty acid intake and MS, including an effect upon myelin itself, an abnormality of PUFA metabolism and an effect of PUFA on immunosuppression.
The problem with most of the epidemiological studies upon which hypotheses are based is that the group studied in Norway, the Ashkenazi and Yemenite Jews in Israel and the German and Italian Cantons in Switzerland also differ in their genetic make-up and the dietary differences are a reflection of cultural and ethnic differences which may be the real reason for the differing rates of MS.
Biochemistry. The initial epidemiological evidence appeared to receive support from the field of lipid biochemistry when, in the 196Os, papers were published which indicated that there was a reduction in the proportion of arachidonic and linolenic acids in the lecithin fraction of apparently normal myelin from the brains of patients with MS when compared to controls (Baker et al., 1963; Gerstl et al., 1965) . It was originally assumed that this alteration was seen in the normal white matter of MS patients, although Allen & McKeown (1979) reported that the apparently normal myelin in the brains of MS patients might still be the site of partial demyelination. Other authors were not able to confirm the original reports of differences in the proportion of arachidonic and linolenic acid in the brains of MS patients (Arnetoli et al., 1969). The idea of an abnormality of lipids in MS was further strengthened by the reports of abnormally low proportions of certain PUFA, especially linoleic acid, in the serum, platelets and erythrocytes of patients with MS (Baker et al., 1964 (Baker et al., , 1965 (Baker et al., , 1966 Gul et al., 1970) . These original reports have received independent confirmation from other laboratories (Tichy et al., 1969; Neu, 1983) Although not conclusive, these studies suggest that there may be an abnormality of the proportion of PUFA of w? type in MS, though whether this is due to a deficiency in dietary intake or an alteration in metabolism (Thompson, 1966) remains uncertain. There is no evidence that patients with MS fail to absorb dietary polyunsaturates and there is no biochemical information relating to the levels of w3 PUFA in patients with MS.
Clinical trials
Despite the problems in the interpretation of both the epidemiological and biochemical data, neurological clinicians felt that there was sufficient evidence to support the testing in the clinical field of the effect of dietary supplementation with PUFA in patients with MS. Studies have been undertaken during the past 15 years with PUFA of both the wn and w3 families.
w6 PUFA Linoleic acid (C18:2 oh). The first controlled double-blind trial of dietary supplementation with linoleic acid was reported in 1973 from Belfast and London (Millar et al., 1973) . There were 75 patients in the trial, 36 received treatment with 17.2 g of linoleic acid daily and 39 received oleic acid in a dose of 7.6 g daily; these patients were regarded as the control group. At the end of 2 years, there appeared to be benefit for the treated group, in that relapses were less frequent, less severe and of shorter duration than in the control group, but there was no difference in the progression of the disease.
A second controlled, double-blind trial in Newcastle upon Tyne (Bates et al., 1978) was undertaken to determine the effect of dietary supplementation with linoleic acid in patients with acute remitting MS and those with the chronic patients with acute remitting disease. One hundred and seventy-two such patients were identified all of whom had been followed for at least 28 months; 87 had received active treatment and 85 placebo. The two groups were similar in terms of entry criteria (Table 1 ). The analysis was designed to examine the relationship between the duration and severity of the disease, and the effectiveness of linoleic acid therapy. The groups were therefore divided into those with mild disease and severe disease, and those with a disease duration of less than 5,6-10 and more than 10 years. The results are shown in Tables 2 and 3. In Table 2 , it can be seen that the deterioration in clinical status (a negative score indicates that the patients are worse) is less marked in the groups with mild diseases who were given linoleic acid and that the severity of relapses is less in both groups so treated. Table 3 shows that the deterioration in overall condition is least in patients with a short history who were provided with treatment. These results have been taken to indicate that dietary supplementation with linoleic acid does have a mild beneficial effect for patients with MS who are treated early in the course of the disease, and who have only a minor disability. All studies showed that it was possible to increase the proportion of linoleic acid in the serum of patients with MS by dietary supplementation. w.3 PUFA The suggestion that PUFA might exert their effect in MS via an immunological mechanism and the evidence for the low prevalence of MS in fish-eating countries, led to the conclusion that the w j PUFA, which gave rise to the '3' series of prostanoids, might have a different and better effect. This led to the setting up of a trial of the effect of fish body oils in MS. A multicentre study of patients with acute remitting MS given dietary supplementation with fish body oils, containing eicosapentanoic and docosahexanoic acids, has been undertaken in Newcastle upon Tyne, London and Belfast. Three hundred and twelve patients with acute remitting MS have been studied in the trial, of whom 155 received active treatment with 1.7 g of eicosapentanoic acid (Cza,. 03) and 1.1 g of docosahexanoic acid (CZZ:h w 3 ) daily, and the 157 control patients received olive-oil capsules. Information about the patients entering the trial is shown in Table 4 and at the end of 2 years' treatment it was apparent ( Table 5 ) that, although there was no statistically significant difference between the two groups, there was a trend in favour of treatment resulting in less patients who had deteriorated (P= 0.07). All patients in both groups were given advice to increase their intake of w6 PUFA and it may therefore be assumed that the addition Fig. 1 . The possible role of PUFA of w j acids provides a mild benefit in addition to that already recorded with the w6 family. None of these dietary manipulations in MS has made a great difference to the outcome, but there does appear to be a genuine, though mild, improvement with supplementation of the diet by both w6 and w j PUFA.
Effect of PUFA in MS
The role of fatty acids in multiple sclerosis is uncertain at present, but almost certainly is more complex than was originally believed (Mertin & Meade, 1977) . The potential ways in which these fatty acids could exert their effect are summarized in Fig. 1 , but we now need more biochemical data to explain the potential mechanisms for their action before further clinical trials are undertaken.
